STAT+: Biotech accelerator Curie.Bio extends its reach with new $380 million fund
Industry veterans Alexis Borisy and Zach Weinberg had plenty of reasons to celebrate their new…
Category: biotechnology
One firm, two conflicting takes on Alnylam’s HELIOS-B
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Former Moderna executive launches genome editing company
As chief medical officer of Moderna, Tal Zaks used to be skeptical of genome editing….
The 42 best books and podcasts on health and science to check out this summer
Summer is officially here, and whether you’re relaxing in the great outdoors or riding out…
STAT+: Grail, aiming to launch a blood test for cancer, faces host of challenges as it debuts on Nasdaq
On Tuesday, shares of Grail, the liquid biopsy company that hopes that its test, Galleri,…
The findings from Alnylam’s highly anticipated readout
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Alnylam reports positive results for heart drug in pivotal study, likely clearing path to approval
Alnylam Pharmaceuticals said Monday that its treatment for an increasingly common heart condition cut the…
STAT+: Vertex reports positive results in stem cell trial for type 1 diabetes
ORLANDO — Twelve people with type 1 diabetes who received a therapy derived from stem…
STAT+: What the Sarepta decision means for Duchenne patients, the company, and the FDA
Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration…
Can JAK inhibitors bolster checkpoint inhibitors?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy
For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official…
STAT+: Ginkgo Bioworks lays off 158 employees, with more to come
BOSTON — Ginkgo Bioworks, the once-high-flying Boston life sciences firm, on Thursday said it has…
STAT+: FDA approves Sarepta’s Duchenne gene therapy for nearly all patients
The Food and Drug Administration on Thursday approved Elevidys, Sarepta’s gene therapy for Duchenne muscular…
STAT+: Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments
After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement…
Listen: Fauci’s memoir, Alnylam’s tenuous trial, and a mid-year review
Can Alnylam find success with its latest cardiac treatment after tweaking the trial? And did…
STAT+: Zealand’s amylin-targeting drug shows early potential in obesity
Zealand Pharma on Thursday reported early positive results of an investigational obesity drug that activates…
STAT+: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial
Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected…
.jpg)
Lilly takes more actions against unapproved versions of Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
A biotech’s binary bet ends badly
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease
A 10-person startup called Marea said Tuesday that it had raised $190 million to help…
FDA offers new guidelines for Covid-19 vaccine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
J.P. Morgan has officially jumped into early stage biotech investing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)
On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us…
Biopharma execs cheer Supreme Court for upholding FDA authority in abortion pill case
On Thursday, the Supreme Court rejected an effort by anti-abortion doctors to bar the mailing…
With Avidity and Pfizer, gene therapy enters a phase
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Will Geron be acquired? The long-short view
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
What do Parkinson’s and obesity have in common?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy
Avidity Biosciences said Wednesday morning that an experimental medicine successfully knocked down the gene behind…
Three scientists win Kavli Prize for nanoscience in biomedicine
Three scientists — Robert Langer, Paul Alivisatos, and Chad Mirkin — were awarded the 2024…
Bernie Sanders calls vote to subpoena Novo Nordisk U.S. head over Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders has called a vote to subpoena the…
Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biotech co-founded by entrepreneur Bob Langer is testing a new approach to developing obesity treatments
A new company founded by a group of biotech veterans, including Bob Langer, came out…
STAT+: FDA advisers unanimously recommend approval of Eli Lilly’s Alzheimer’s disease treatment
Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval…
.jpg)
STAT+: Moderna says data show its combination Covid-flu vaccine generates a strong immune response
Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza…
Vanda Pharmaceuticals has another suitor
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Psychedelics at the FDA, ASCO recap, & MorphoSys update
How did advisers react to the first psychedelic therapy to go before the Food and…
STAT+: At BIO, signs Congress’ tough stance on China is chilling biotech relationships
SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese…
STAT+: FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental…
Novovax will be able to supply Covid-19 vaccines this fall
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study
Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of…
Testing begins for a new form of PrEP
Want to stay on top of the science and politics driving biotech today? Sign up to get…
ASCO Takeaways: Winners, snoozers, the China question and the art of cancer care
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
Operation Warp Speed but for rare disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug
CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly…
STAT+: Illumina board agrees to spin off Grail, as divestment plans proceed
Illumina said Monday afternoon that its board of directors had approved a spin-off of its…
STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial
CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with…
Can AstraZeneca make good on its promise?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Structure Therapeutics oral GLP-1 drug led to weight loss in two studies
Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two…
STAT+: Agios drug reduces blood transfusions in patients with beta-thalassemia, study shows
Agios Pharmaceuticals said Monday that its drug called mitapivat reduced the need for blood transfusions…